EUVIMEDEUVIMED entdecken
Leitlinie

Circulating Tumor DNA Testing in Solid Tumors and Lymphoma: ASCO Guideline

Christina M Lockwood iD, Hans J Messersmith iD, Annette S Kim iD, Padma Sheila Rajagopal iD, Umang Swami iD, Rena Xian iD, Dara Aisner iD, Maria E Arcila iD, Florence Kurttila, Christine M Lovly iD, Jason D Merker iD, Kanika G Nair iD und 5 weitere

JCO Oncology Practice · 2026-09 · 22 (9) · 1468-1489

DOI: 10.1200/op-26-00311 ↗

Kurz gefasst

Leitlinie in der Zeitschrift JCO Oncology Practice, 2026-09. Verfasst von Christina M Lockwood und 16 weiteren Autor:innen. Beteiligte Einrichtung: University of Washington School of Medicine, Seattle, WA. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Lymphoma, Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 95 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases, or stages of diseases. Guidance is based on review and analysis of relevant literature and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and 2 (online only) for more . PURPOSE To provide guidance on the use of circulating tumor DNA (ctDNA) testing in patients with solid tumors or lymphoma. METHODS A systematic review by a multidisciplinary panel with patient representation was conducted. The PubMed database was searched from January 2017 to February 2025. Guideline recommendations were based on consideration of the identified evidence. RESULTS Fifty-four meta-analyses and 22 study reports were identified, including reports of seven randomized trials. RECOMMENDATIONS ctDNA testing for tumor genetic alterations may be used in situations where: tumor tissue testing is challenging, not feasible, or tumor biopsy represents unacceptable risks to the patient; tumor tissue testing results may not be available within a clinically actionable time frame to determine appropriate management options; or a drug's regulatory approved indication allows for or requires ctDNA testing. If ctDNA testing results are negative, inconclusive, or inconsistent with the clinical scenario, tissue-based confirmation should be sought. Other than testing for genetic alterations, ctDNA testing may be offered if a specific, evidence-based action can be taken with the results or there is conflict or ambiguity with standard-of-care assessment that may be resolved by ctDNA testing. Fractional, percentage, or concentration-based measures of ctDNA or total cell-free DNA concentration are not recommended as a surrogate measure of disease. The panel recognizes this is a rapidly evolving field and guidelines are anticipated to change, bringing in tumor-type specific recommendations and incorporating more data on molecular residual disease settings. Additional information is available at www.asco.org/molecular-testing-and-biomarkers-guidelines .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Circulating Tumor DNALymphomaNeoplasmsHumansPractice Guidelines as Topic

Substanzen

Circulating Tumor DNA

Autor:innen und Institutionen

  • University of Washington School of Medicine, Seattle, WA.
  • American Society of Clinical Oncology, Alexandria, VA.
  • University of Michigan, Ann Arbor, MI.
  • National Cancer Institute, Bethesda, MD.
  • Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.
  • Johns Hopkins School of Medicine, Baltimore, MD.

ORCID-Profile: Christina M Lockwood, Hans J Messersmith, Annette S Kim, Padma Sheila Rajagopal, Umang Swami, Rena Xian, Dara Aisner, Maria E Arcila, Christine M Lovly, Jason D Merker, Kanika G Nair, Atara Isaiah Ntekim, Apostolia Maria Tsimberidou, Nicholas C Turner, Stacy W Gray

Zitieren

APA

Lockwood, C. M., Messersmith, H. J., Kim, A. S., Rajagopal, P. S., Swami, U., Xian, R., Aisner, D., Arcila, M. E., Kurttila, F., Lovly, C. M., Merker, J. D., Nair, K. G., Ntekim, A. I., Sheen, M. A., Tsimberidou, A. M., Turner, N. C., & Gray, S. W. (2026). Circulating Tumor DNA Testing in Solid Tumors and Lymphoma: ASCO Guideline. JCO Oncology Practice, 22(9), 1468-1489. https://doi.org/10.1200/op-26-00311

Vancouver

Lockwood CM, Messersmith HJ, Kim AS, Rajagopal PS, Swami U, Xian R, et al. Circulating Tumor DNA Testing in Solid Tumors and Lymphoma: ASCO Guideline. JCO Oncology Practice. 2026;22(9):1468-1489. doi:10.1200/op-26-00311

BibTeX
@article{Lockwood2026,
  author = {Lockwood, Christina M and Messersmith, Hans J and Kim, Annette S and Rajagopal, Padma Sheila and Swami, Umang and Xian, Rena and Aisner, Dara and Arcila, Maria E and Kurttila, Florence and Lovly, Christine M and Merker, Jason D and Nair, Kanika G and Ntekim, Atara Isaiah and Sheen, Melanie Anne and Tsimberidou, Apostolia Maria and Turner, Nicholas C and Gray, Stacy W},
  title = {Circulating Tumor DNA Testing in Solid Tumors and Lymphoma: ASCO Guideline},
  journal = {JCO Oncology Practice},
  year = {2026},
  volume = {22},
  number = {9},
  pages = {1468--1489},
  doi = {10.1200/op-26-00311}
}
Kostenlos starten →